Before moving a pharmaceutical or biotech process, ask a plain question: what must the receiving team know, do, and show before you accept the handoff? CDMO technology transfer deserves that level of detail—not just a start date and a promise that the site is ready.
Use this guide to shape the buyer’s brief, review a partner’s transfer plan, and set decision gates. Keep process design, quality decisions, and regulatory requirements with qualified technical teams. The focus here is how leaders can ask better questions.
What is CDMO technology transfer?
CDMO technology transfer is the handoff of product and process knowledge to a contract development and manufacturing organization. For a buyer, the task is to agree what moves, what the receiving team must understand, and what evidence will support acceptance. Treat it as a shared plan, not a file delivery.
The ISPE Boston-hosted presentation on technology transfer describes its goal as transferring product and process knowledge. If the provider terminology is new, start with what is a CDMO. This guide addresses the handoff rather than general biotech outsourcing or partner selection.
Why does CDMO technology transfer matter to the buyer?
It matters because the buyer needs a basis for accepting the handoff—not simply a record that documents were sent. Ask the receiving team to explain what it understands, what remains open, and what evidence will support the next decision.
An Outsourced Pharma overview emphasizes early alignment on process readiness, analytical strategy, and governance. Use those as separate review topics. A schedule should not stand in for a readiness review, and a completed meeting should not stand in for an accepted deliverable.
Use CDMO technology transfer planning to surface unresolved decisions before making firm commitments. Ask which assumptions are still open, who can close them, and which milestones depend on their answers. For each risk, request a named owner and an agreed basis for closure.
What should you agree before the transfer starts?
Start CDMO technology transfer with a written scope that both sides can explain in the same terms. Name the process, the sending and receiving teams, the intended manufacturing stage, the included work, and the exclusions.
If fill-finish is part of the move, include that work explicitly. Do not bury it under a broad pharmaceutical manufacturing label. Likewise, do not let a CMO or CDMO label replace the statement of work.
Include your CMC, quality, and regulatory leads in defining the scope. Ask them to identify the applicable technical reviews, qualification, validation, and filing work. This guide does not set those requirements.
Assign a buyer-side decision owner and a receiving-side transfer lead. Then distinguish who supplies information, who reviews it, who accepts it, and who resolves disagreements. Put escalation routes in writing before a disputed decision arises.
What belongs in a CDMO technology transfer package?
Organize the proposed package around questions the receiving team must answer. Ask technical leads to determine the records and level of detail appropriate to the process; do not treat the following list as a universal specification.
- Process understanding: What is the agreed process description, and what supporting knowledge explains the choices behind it?
- Supporting records: Which development records, manufacturing records, material information, and prior issue summaries belong in scope?
- Testing approach: Which methods and criteria will the technical teams use to assess the handoff, and who accepts the results?
- Receiving-site gaps: What differences need evaluation, what information is missing, and who owns each assessment?
- Decision rules: What evidence supports proceeding, pausing, changing scope, or accepting a deliverable?
- Access and permissions: Who may use the records and knowledge, and how will the teams manage access, ownership, and retention?
For each item, record its owner, version, review status, and acceptance route. Ask the receiving team to state whether it has merely received the material or has reviewed and accepted it for the agreed purpose.
How should CDMO technology transfer work in practice?
Use decision gates tied to evidence rather than dates alone. The sequence below is a buyer-side planning approach, not a manufacturing protocol. Have the technical team adapt it to the project.
First, review the starting point
Ask both teams to describe what is known, what is missing, and what must be resolved before execution. Request a gap list with owners, dependencies, and proposed closure evidence.
Have the receiving team explain its understanding back to the sending team. Focus the discussion on unclear decisions and missing context, not on whether everyone attended the kickoff.
Next, agree the execution plan
Connect each proposed activity to a deliverable and a decision. Ask what the activity is meant to establish, how the result will be reviewed, and what happens if it does not meet the agreed criteria.
Separate technical work from governance work. Give issue reviews, change decisions, and acceptance reviews their own owners and place in the schedule.
Then, review results before advancing
At each gate, compare the available evidence with the agreed criteria. Ask reviewers to record their decision and the reason for it. Where an issue remains open, identify whether it prevents progress or requires a defined follow-up.
Do not equate spending the planned time with completing the planned work. Ask what has been accepted and what remains unresolved.
Finally, define the handoff out of transfer
Before closing the project, ask who owns remaining actions, where the accepted records will live, and how the receiving team will access support. Make the end of transfer a documented decision rather than a final calendar meeting.
What mistakes should companies avoid?
During CDMO technology transfer, challenge four shortcuts in the proposed plan.
Treating delivery as acceptance. Ask for distinct statuses for material sent, reviewed, and accepted. Do not use one completion label for all three.
Leaving assumptions inside the estimate. Request the staffing, information, site-readiness, and review assumptions behind each major milestone. Assign an owner to test each material assumption.
Making ownership collective. Replace “the teams will resolve this” with a named decision owner, a deadline, and an escalation route. Keep contributors visible without blurring authority.
Changing scope without showing the consequences. Ask for each proposed change to identify its effect on deliverables, dependencies, cost, and acceptance criteria. Resolve the change before treating the revised plan as the baseline.
How should you measure CDMO technology transfer success?
Measure success against the scope and acceptance criteria agreed for the project. Use schedule and cost as supporting views, not substitutes for technical acceptance. Ask quality and regulatory leads which decisions require their review.
A buyer-side progress scorecard
Use these proposed measures to structure project reviews. Set targets with the responsible teams rather than borrowing a universal benchmark.
| Measure | What to track | Buyer’s question |
|---|---|---|
| Deliverable acceptance | Agreed deliverables due, submitted, reviewed, and accepted | What has been accepted, rather than simply sent? |
| Open issues | Issue status, owner, due date, and closure evidence | Which unresolved items affect the next decision? |
| Gate decisions | Planned and actual decisions, with reasons for changes | Is progress supported by the required evidence? |
| Budget control | Committed cost, spend to date, forecast, and scope changes | Does the forecast still match the agreed work? |
Review the measures together. If a milestone moves, ask whether the cause was missing information, added scope, a technical issue, or a delayed decision. Keep the explanation attached to the forecast so leaders can act on it.
What should a timeline and budget include?
A useful CDMO technology transfer estimate should show its assumptions. Ask for document review, receiving-site assessments, planned technical work, decision time, staffing, and contingency to be explained separately.
Request a dependency view as well as a date view. Which activities can begin now? Which depend on information, materials, capacity, or an earlier decision? Ask what would change the forecast and when you would learn about that change.
For cost, compare included work, exclusions, change terms, and acceptance criteria—not just the total. Where an item remains undefined, request a clear method for estimating and authorizing it later.
What should commercial teams say about transfer capability?
Keep CDMO technology transfer claims tied to what technical teams can substantiate. Separate a description of the service offered from evidence that a particular project met its agreed criteria.
For teams responsible for life sciences marketing, make buyer questions part of the content brief: what is in scope, who owns the handoff, and what evidence can a prospect request? Use approved project-specific facts only when they are available for public use.
Before signing, ask the proposed partner to walk through one decision gate: its inputs, owner, acceptance criteria, and escalation route. Use that discussion to test whether the proposal explains how decisions will be made—not merely when work is expected to finish.
About Bob Generale
Bob Generale is President of Percepture.
